FoundationOne Liquid CDx demonstrates clinical validity for detecting BRAF V600E mutations in colorectal cancer, supporting its use in precision medicine.
The study highlighted key demographic and clinical characteristics in LBx test-evaluable subsets, emphasizing the importance of accurate mutation identification.
Assessment utilized clinical data from colorectal cancer patients to determine the effectiveness of FoundationOne Liquid CDx in mutation detection.
The findings call for the broader adoption of liquid biopsy techniques to improve treatment outcomes in colorectal cancer management.
Abstract
Demographics and clinical characteristics in the LBx test-evaluable and -unevaluable subsets